Lee Peyton1, Alfredo Oliveros1, Maximilian Tufvesson-Alm2, Lilly Schwieler2, Phillip Starski3, Göran Engberg2, Sopie Erhardt2, Doo-Sup Choi1,3,4. 1. Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine and Science, Rochester, MN, USA. 2. Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden. 3. Neuroscience Program, Mayo Clinic College of Medicine and Science, Rochester, MN, USA. 4. Department of Psychiatry and Psychology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
Abstract
Kynurenic acid (KYNA), a glial-derived metabolite of tryptophan metabolism, is an antagonist of the alpha 7 nicotinic acetylcholine receptor and the glycine-binding site of N-methyl-d-aspartate (NMDA) receptors. Kynurenic acid levels are increased in both the brain and cerebrospinal fluid of several psychiatric disorders including bipolar disorder, schizophrenia, and Alzheimer disease. In addition, pro-inflammatory cytokines have been found to be elevated in the blood of schizophrenic patients suggesting inflammation may play a role in psychiatric illness. As both pro-inflammatory cytokines and KYNA can be elevated in the brain by peripheral lipopolysaccharide (LPS) injection, we therefore sought to characterize the role of neuroinflammation on learning and memory using a well-described dual-LPS injection model. Mice were injected with an initial injection (0.25 mg/kg LPS, 0.50 mg/kg, or saline) of LPS and then administrated a second injection 16 hours later. Our results indicate both 0.25 and 0.50 mg/kg dual-LPS treatment increased l-kynurenine and KYNA levels in the medial pre-frontal cortex (mPFC). Mice exhibited impaired acquisition of CS+ (conditioned stimulus) Pavlovian conditioning. Notably, mice showed impairment in reference memory while working memory was normal in an 8-arm maze. Taken together, our findings suggest that neuroinflammation induced by peripheral LPS administration contributes to cognitive dysfunction.
Kynurenic acid (KYNA), a glial-derived metabolite of tryptophan metabolism, is an antagonist of the alpha 7 nicotinic acetylcholine receptor and the glycine-binding site of N-methyl-d-aspartate (NMDA) receptors. Kynurenic acid levels are increased in both the brain and cerebrospinal fluid of several psychiatric disorders including bipolar disorder, schizophrenia, and Alzheimer disease. In addition, pro-inflammatory cytokines have been found to be elevated in the blood of schizophrenicpatients suggesting inflammation may play a role in psychiatric illness. As both pro-inflammatory cytokines and KYNA can be elevated in the brain by peripheral lipopolysaccharide (LPS) injection, we therefore sought to characterize the role of neuroinflammation on learning and memory using a well-described dual-LPS injection model. Mice were injected with an initial injection (0.25 mg/kg LPS, 0.50 mg/kg, or saline) of LPS and then administrated a second injection 16 hours later. Our results indicate both 0.25 and 0.50 mg/kg dual-LPS treatment increased l-kynurenine and KYNA levels in the medial pre-frontal cortex (mPFC). Mice exhibited impaired acquisition of CS+ (conditioned stimulus) Pavlovian conditioning. Notably, mice showed impairment in reference memory while working memory was normal in an 8-arm maze. Taken together, our findings suggest that neuroinflammation induced by peripheral LPS administration contributes to cognitive dysfunction.
Intensive research into the molecular pathophysiology of neuropsychiatric disorders
has highlighted the importance of the neuroinflammation-induced activation of the
kynurenine pathway (KP) of tryptophan catabolism in schizophrenia (SCZ), bipolar
disorder (BP), and major depressive disorder (MDD). Kynurenic acid (KYNA) is an
endogenous molecule derived from the metabolism of tryptophan (TRP) and released by
astrocytes or microglia.[1-4] Briefly, pro-inflammatory
cytokines induce the rate-limiting enzymes, indoleamine 2,3 dioxygenase (IDO-1) and
tryptophan 2,3, dioxygenase (TDO2), of the KP.[5,6] The multistep chemical
transformation of TRP into KYNA along the KP is known to regulate immune response
and is hypothesized to play an integral role in the counter-regulatory mechanism
pertaining to inflammation.[7] Kynurenic acid, an endogenous molecule derived from this pathway, is
synthesized and released by astrocytes.[1-4] In high concentrations, KYNA is
a competitive antagonist of the glycine-binding site of
N-methyl-d-aspartate receptors (NMDARs).[8,9] In addition, KYNA is known to
modulate α7-nicotinic acetylcholine receptors (α7nAChRs).[10] Neurotransmission through N-methyl-d-aspartate
(NMDA) and nAChRs are crucial for a large number of cognitive functions.
Interestingly, KYNA is found to be elevated in the cerebrospinal fluid (CSF) and
postmortem brain tissue in patients diagnosed with SCZ and BP which has prompted the
hypothesis that increased brain KYNA concentrations in the brain may underscore the
glutamatergic and cholinergic alterations of cognitive function observed in
individuals with SCZ and BP.[11-18] Interestingly, increased
synthesis of endogenous KYNA has been demonstrated to impair spatial and contextual
fear memory in rats.[19] Furthermore, brain-penetrant inhibitors of the enzyme kynurenine
aminotransferase (KAT) II, which is responsible for neosynthesis of KYNA, have been
shown to markedly reduce brain KYNA levels[20-22] and to improve cognitive
functions in rodents and non-human primates.[20] Mice with targeted KAT II deletion exhibit decreased brain KYNA levels and
enhanced performance in tests of cognitive paradigms.[23] Overall, the existing literature stresses the importance of KYNA as a
significant player in higher cognitive functions.Compared to single-shot LPS (1×-LPS), 2×-LPS administration increase brain KYNA
concentrations in CSF of mice.[1] In our study, we investigate the effects of dual-injection of
lipopolysaccharide (2×-LPS) on brain KYNA production and characterize the resulting
behavior anomalies pertaining to cognitive function and memory. By employing this
paradigm, we investigated KYNA concentrations from medial pre-frontal cortex (mPFC)
whole tissue lysate of adult C57BL6/J male mice aged 12 weeks following 2×-LPS
administration across 144 hours post LPS injection. In addition, we examined the
behavioral effects of elevated KYNA in Pavlovian conditioning, the 8-arm radial
maze, sensorimotor gating, and motor coordination and motor incoordination. Our
experiments highlight that neuroinflammation stemming from peripheral 2×-LPS
treatment induces dysregulation of the KP which may further serve as a useful model
to study the subtle cognitive impairments associated with psychiatric disorder.
Materials and Methods
Animals
Male C57BL/6J mice used for this study were acquired from Jackson Laboratories
(Bar Harbor, ME, USA). All mice used in this study were age matched at –3 months
of age and were cared for as previously described.[1,24] Food and water were
available ad libitum, although food was restricted only in mice that underwent
Pavlovian conditioning and 8-arm radial maze (8-ARM) testing. Animals were group
housed with 5 mice per cage on a 12-hour lights on/off cycle (lights on at
06:00 hours). Temperature was maintained at 25°C and humidity between 40% and
60%. Experiments were approved by and performed in accordance with the
guidelines of the Mayo Clinic Institutional Animal Care and Use Committee in
accordance with NIH guidelines.
Experimental design
Mice in this study were separated into 3 groups that received either consecutive
dual LPS injections (2×-LPS; Escherichia coli serotype 0111:B4,
Sigma Aldrich, St. Louis, MO, USA) at 0.25 mg/kg or 0.5 mg/kg (0.1 mL/10 g body
weight i.p.) or saline vehicle (0.9%), freshly prepared prior to initial
(T0) LPS injection. Vehicle or LPS were initially administered at
T0 with a second injection commencing 16 hours later
(T1; Figure
1A) as previously described.[1] Mice used for this study were weighed daily to assess changes in body
weight during Pavlovian conditioning and 8-ARM testing as well as to monitor
health as a result of LPS administration. Given that LPS administration is known
to decrease body weight,[25] we matched food restriction weight with LPS-induced decreases in body
weight for behavioral comparisons during Pavlovian conditioning and 8-ARM
testing.
Figure 1.
Double-LPS treatment activates KP pathway. (A) Experimental schedule used
to assess the effects of dual-LPS treatment on cognitive behavior. (B)
HPLC measurement of l-kynurenine 24 hours post initial LPS
injection. n = 5/treatment. (C) HPLC measurement of
kynurenic acid 24 hours post initial LPS injection.
n = 5/treatment. Results are expressed as mean ± SEM.
ANOVA indicates analysis of variance; HPLC, high-performance liquid
chromatography; KP, kynurenine pathway; LPS, lipopolysaccharide; mPFC,
medial pre-frontal cortex; SEM, standard error of the mean.
*P < .05, **P < .01,
***P < .001; 1-way ANOVA.
Double-LPS treatment activates KP pathway. (A) Experimental schedule used
to assess the effects of dual-LPS treatment on cognitive behavior. (B)
HPLC measurement of l-kynurenine 24 hours post initial LPS
injection. n = 5/treatment. (C) HPLC measurement of
kynurenic acid 24 hours post initial LPS injection.
n = 5/treatment. Results are expressed as mean ± SEM.
ANOVA indicates analysis of variance; HPLC, high-performance liquid
chromatography; KP, kynurenine pathway; LPS, lipopolysaccharide; mPFC,
medial pre-frontal cortex; SEM, standard error of the mean.*P < .05, **P < .01,
***P < .001; 1-way ANOVA.
Tissue extraction
Mice were rapidly anesthetized using CO2, followed by decapitation.
Whole brains were extracted and subsequently dissected to isolate mPFC. Tissue
was immediately snap frozen in dry ice and stored in a −80°C freezer until used
for biochemical assessment.
High-performance liquid chromatography analysis
Isolated mPFC tissue samples were mixed with a 1:5 (tissue to reagents) ratio of
0.4M perchloric acid (PCA), 0.1% sodium metabisulfite
(Na2S2O5), and 0.05% EDTA. Each mPFC tissue
sample was homogenized using 0.5 mm zirconium oxide beads in a Storm 24 magnetic
Bullet Blender for 3 minutes with speed set to 4 (Next Adventure Inc., Averill
Park, NY, USA). Next, the samples were centrifuged (21 000 × g) at 4°C for
5 minutes, and supernatant retained. The supernatant was mixed with 10% volume
of 70% PCA and again centrifuged (21 000 × g) for an additional 5 minutes. The
supernatant was then transferred to a new 1.5-mL Eppendorf tube and immediately
stored at −20°C for later use.To measure KYN and KYNA levels in the respective brain regions, an isocratic
reverse-phase high-performance liquid chromatography (HPLC) system with a UV
detector (Shimadzu SPD-10A, 360 nm) and fluorescence detector (FP-2020 Plus,
Jasco Ltd., Hachioji, Japan; 344 nm excitation wavelength, 398 nm emission
wavelength 18 nm bandwidth) was used. Samples (50 µL) were injected of mice
treated with either vehicle (n = 5) or 2×-LPS (0.25 and 0.50 mg/kg,
n = 5/treatment dose). The mobile phase consisting of 50 mM sodium acetate and
7% acetonitrile (pH 6.2) was pumped through a ReproSil-Pur C18 column
(4 mm × 150 mm, Dr. Maisch GmbH, Ammerbuch, Germany). A second mobile phase
consisting of 0.5M Zinc acetate in dH2O was delivered post-column,
immediately preceding the fluorescence detector, by a Pharmacia P-500 (GE
healthcare; Uppsala, Sweden) with a flow rate of 10 mL/h. Any signals received
from the detectors were transferred to a computer equipped with Datalys Azur
(Grenoble, France) for analysis. The retention time for KYN was 4 minutes, and
the retention time for KYNA was 7 minutes.
Behavior Testing
Pavlovian conditioning
Mice were allowed 30 minutes of acclimation in the testing room prior to baseline
measurement of general activity inside standard mouse operant chambers
(MED-307A-B2, Med Associates Inc., St. Albans VT). For baseline measurement,
mice were allowed to freely explore the operant chamber for 30 minutes with the
house light (HL) and cubicle fan (CF) turned on. Assessment of baseline occurred
before 2×-LPS or vehicle administration. Total session time, left and right
nosepokes (inactive), and magazine head-entries (magazine-entries) were recorded
(ENV-302D head entry detector, Med-Associated). Given that previous studies have
shown deficits in conditioned stimulus (CS+) learning during LPS treatment,[26] we questioned whether 2×-LPS administration would attenuate the
acquisition of stimulus-reward learning during Pavlovian conditioning.[27,28] To control
for the decreased weight of the 2×-LPS-treated mice, vehicle-treated mice were
food restricted and weights were closely monitored daily during conditioning. To
establish a tone-reward contingency during conditioning, mice were given a
random series of CS+ tone cues (65 dB and 0.25 seconds duration; ENV-323HAM,
4500 Hz Sonalert, Med-Associates), paired with delivery of a 10 µL sucrose
reward.[24,29] During conditioning, the CS+ was randomly spaced by
intervals (2-60 seconds), such that on average, a reward was delivered every
15 seconds. The acquisition of Pavlovian learning was determined by measuring
the latency between the CS+ and the subsequent CS+ potentiated magazine entry
(CS+ reaction time) that resulted, thereby providing a measurement of
stimulus-induced attentional processing. Sessions were terminated after reaching
a designated number of CS+ presentations and indicated by HL and CF turning off.
Average reaction time was determined as: Average Reaction Time = [(sum of
latency from each trial/CS+ presentations)].The effects of vehicle or 2×-LPS injection (0.25 and 0.50 mg/kg) on Pavlovian
conditioning were examined in 3 groups of mice. For baseline assessment during
Pavlovian conditioning (Experiment 1), we measured changes across testing
sessions in reaction time latencies between CS+ presentations and the next
immediate magazine entry to determine acquisition of conditioning. We also
investigated the number of inactive hole magazine entries, as well as the number
of nose-poke entries to determine how LPS affects general behavior during
conditioning. Baseline was conducted prior to T0 vehicle or 2×-LPS
administration. Pavlovian conditioning was assessed at 48, 72, and 96 hours
after T0 administrations (Veh n = 13, LPS 0.25 mg/kg n = 10, LPS
0.50 mg/kg n = 5). Pavlovian conditioning sessions concluded after 65 CS+
presentations.
Accelerated rotarod
To probe the effects of 2×-LPS treatment on motor function, a mouse rotarod
treadmill (UGO Basile, Verese, Italy) was used. A program was used to
incrementally accelerate from 2 to 40 r/min over a time interval of 300 seconds.
The time latency it took for a mouse to fall from the treadmill was the output
measure of motor coordination. Each group of mice (vehicle n = 8, LPS 0.25 mg/kg
n = 5, LPS 0.50 mg/kg n = 4) performed rotarod resting at 16 and 24 hours post
T0 administration.
Radial 8-ARM maze
Mice undergoing 8-ARM testing were subjected to food restriction to 85% of their
ad libitum feeding body weight. A typical 8-ARM (MED-RAM-U-1M, Med Associates,
St. Albans, VT) was used to assess spatial learning and memory in mice after
treatment with either vehicle or 2×-LPS. The maze was elevated 65 cm on a table
and contained an octagonal central chamber equipped with 8 computer-controlled
guillotine doors. Connected to the central chamber, there were 8 arms that
extended from each side of the central chamber. The 8 extended arms were of
equal length (35 cm long × 7.25 cm wide) and composed of transparent plastic to
allow mice the use of external visual cues as a support for spatial navigation.
At the distal end of each arm extending from the central chamber, there was a
food trough equipped with sensors that would dispense 20 mg chocolate food
pellets (Bio-Serv, Flemington NJ, USA) when activated.During behavior testing, all mice were allowed 30 minutes to acclimation in the
testing room prior to beginning the test. For habituation, mice were allowed to
acclimate in center chamber for 2 minutes after which all guillotine doors
opened allowing the mice to freely explore the maze for 10 minutes. During
habituation, all 8 arms and magazine troughs located at the distal end of each
arm were baited with a food pellet to encourage exploration. During subsequent
habituation days, the same procedure was followed except only the magazine
trough was baited, and the session time was decreased to 5 minutes. After
completion of daily habituation, the mice were returned back to home cage. Upon
successful habituation performance (consumption of all 8 baits within 5-minute
session time), the mice were subjected to reference memory and working memory
testing. Mice that failed in habituation performance were excluded from
reference memory and working memory evaluation.For reference and working memory testing, the session time was set to a maximum
of 15 minutes at which point the session would be terminated automatically. To
determine reference or working memory, arms 1, 3, and 7 were not baited, while
arms 2, 4, 5, 6, and 8 were baited. Deficits in these parameters were displayed
by mice that repeatedly entered non-baited arms to check whether there was a
reward at the magazine trough. Mice with intact memory function decrease the
frequency of entries into non-baited arms. Animals were tested for 8 consecutive
days to determine whether 2×-LPS administration induced deficits in long term
memory (LTM) or short-term memory (STM). The following ratio equations shown
below were used to determine working memory and reference memory, as previously
described[30,31]For working memory, this ratio measures the percentage of all arm entries into
the baited arms that resulted in food reinforcement. Therefore, errors were
tabulated as excessive entries into arms where mice first retrieved a reward, in
relation to the number of times animals revisited those arms. The most efficient
performance is for animals to only visit baited arms and only visit them
onceFor reference memory, this ratio is expressed as the number of visits to the
baited arms in relation to entries into all arms. Therefore, reference memory
relies on remembering the location of arms that were baited throughout
habituation and testing, while establishing cognitive distinction of the
location of the arms that never contained a reward (unbaited arms). The most
efficient performance is for animals to primarily visit baited arms and minimize
unbaited arm entries; therefore, errors were tabulated as excessive entries into
unbaited arms relative to baited arms.
Prepulse inhibition
To determine whether 2×-LPS treatment has any effects on sensorimotor gating,
mice were (i.p.) administered initial injection of vehicle (n = 7) or LPS
(0.50 mg/kg; n = 6). Prepulse inhibition (PPI) was measured 16 hours (ie,
T1) after T0 immediately prior to the second LPS
injection and then again tested for PPI at 24 hours following T0 LPS
administration (Figure
1A). Prepulse inhibition testing was conducted as previously
described.[24,28] PPI was measured in sound-attenuating boxes (SR-Lab, San
Diego Instruments, San Diego CA, USA) equipped with a loudspeaker and house
light. Each chamber accommodated a cylindrical plexiglass animal enclosure which
rested on a platform containing a piezoelectric accelerometer mounted beneath.
The piezoelectric accelerometer was responsible for converting vibrations of the
mouse enclosed within the cylindrical plexiglass to analog signals that were
then stored on the computer. At the beginning of the startle stimulus, 65
readings were recorded at 1-ms interval to capture the maximum startle
amplitude. Each session was started with a 5-minute acclimation period
immediately preceded by 4 successive 120 dB stimulus alone trials. These 4
initial trials were excluded from analysis. Four different trial types were then
presented at random: “no stimulus” (background, 65 dB), “Startle pulse alone”
(120 dB; 40 ms), “prepulse alone” (4, 8, 16 dB above background; 20 ms), or
“prepulse + startle pulse” (4, 8, or 16 dB prepulse given 100 ms before 120 dB
startle pulse). The intertrial intervals were randomly varied ranging from 5 to
15 seconds, and all trials were presented 5 times except the “no stimulus” and
“startle pulse alone” trials which were presented 10 times. The average maximum
amplitude of vibrations from the “no stimulus” trial was subtracted from all
startle response values which corrects for baseline movement in the chambers.
The average percentage of acoustic PPI was calculated as: %
PPI = 1 − [(prepulse + startle pulse)/(startle pulse alone)] × 100. For the
startle response calculation, the maximum startle amplitude (v-max) within each
PPI session was used to ascertain the magnitude of this reflex.
Statistical analysis
Measurements of KYN and KYNA concentrations in the mPFC were statistically
analyzed with 1-way analysis of variance (ANOVA). We used repeated-measures
2-way ANOVA (RM 2-way ANOVA) for body weight measurement, accelerated rotarod,
as well as CS+ reaction times, magazine entries, and inactive-hole entries
during Pavlovian conditioning. For behavioral analysis of memory function during
8-ARM testing, we used RM 2-way ANOVA. For PPI, prepulse intensities were
examined using RM 2-way ANOVA. For startle response, analysis was performed with
unpaired 2-tailed Student t test. Statistical significances for
all ANOVAs were followed by Tukey multiple comparisons, where appropriate. For
all reported data, results were considered statistically significant when
P ⩽ .05 and values represented are mean ± SEM (GraphPad
Prism, La Jolla CA, USA).
Results
Double-intraperitoneal injection of LPS increases kynurenine and KYNA in
mPFC
To determine whether peripheral low-dose LPS injection alters kynurenine
metabolism, we intraperitoneally administered with 0.25 mg/kg or 0.5 mg/kg LPS,
followed by administration of a second injection of 0.25 mg/kg or 0.5 mg/kg LPS
16 hours post initial injection (Figure 1A). Mice treated with 0.25 mg/kg
displayed significant increases in KYN (1-way ANOVA, F2,12 = 12.61,
P = .001; Tukey post hoc for vehicle vs LPS 0.25 mg/kg,
P = .04, vehicle vs 0.5 mg/kg, P = .0008,
LPS 0.25 mg/kg vs LPS 0.5 mg/kg, P = .01). In addition, our
findings indicate significant increases in KYNA after double LPS administration
(1-way ANOVA F2,12 = 6.31, P = .01; Tukey post hoc
for vehicle vs LPS 0.25 mg/kg, P = .45, vehicle vs LPS
0.5 mg/kg, P = .01, LPS 0.25 mg/kg vs LPS 0.5 mg/kg,
P = .997). These data suggest that peripheral
administration of low-dose LPS is capable of modulating kynurenine metabolism,
although these effects may be dose dependent.
LPS administration impairs Pavlovian conditioning
To investigate the effects of increased kynurenine metabolism induced by 2×-LPS
administration on cognitive function, mice underwent conditioning to assess
acquisition of Pavlovian learning. Testing was performed at testing 24, 48, and
72 hours post initial (T0) LPS injection (Figure 1A). Our results indicate a
significant main effect of training as both vehicle and LPS injected mice
displayed decreased reaction times to retrieve reward following conditioned
stimulus (CS+) presentations across testing sessions (F2,50 = 19.21,
P < .001) (Figure 2A). Notably, a main effect of
treatment (F2,25 = 9.91, P = .0007) was detected as
0.25 mg/kg and 0.5 mg/kg 2×-LPS administration of significantly impaired
reaction times (Figure
2A) when tested at 48, 72, and 96 hours post T0 LPS
administration (all P < .05). There was no significant
interaction detected. An examination of magazine entries (Figure 2B), an indicator of emotive
reward seeking, detected a drug treatment effect (F2,25 = 9.43,
P = .0009) as both 0.25 and 0.50 mg/kg 2×-LPS treatment
displayed decreased frequency of magazine entries at 72 and 96 hours when
compared to vehicle treatment (all P < .05). However, there
was no effect of training across testing sessions (F2,50 = 2.68,
P = .07), nor an interaction (F4,50 = 1.12,
P = 0.35) (Figure 2B). Investigation of inactive-hole entries (Figure 2C), a measure or
general activity, did not find differences between treatment groups which
suggests that LPS treatment did not impair general exploratory activity and mice
were properly Pavlovian conditioned because any responses into the inactive-hole
did not deliver reinforcement.
Figure 2.
Effects of double-LPS treatment on Pavlovian conditioning. (A) Compared
to vehicle-treated mice, mice undergoing dual-LPS treatment and tested
for acquisition of Pavlovian behavior at 24, 48, and 72 hours post
initial injection displayed slower reaction times to the CS+ stimulus.
(B) In comparison to vehicle treatment, mice treated with 2×-LPS
displayed significantly reduced magazine entries. (C) There was no
difference detected in inactive-hole entries or a change in percentage
free-feeding weight (D). Results are expressed as mean ± SEM.
n = 5/vehicle, n = 10/LPS
0.25 mg/kg, n = 5/LPS 0.50 mg/kg. ANOVA indicates
analysis of variance; CS+, conditioned stimulus; LPS,
lipopolysaccharide; SEM, standard error of the mean.
#P < .05 by 2-way ANOVA. *P < .05
and **P < .01 by Tukey multiple comparisons relative
to vehicle treatment.
Effects of double-LPS treatment on Pavlovian conditioning. (A) Compared
to vehicle-treated mice, mice undergoing dual-LPS treatment and tested
for acquisition of Pavlovian behavior at 24, 48, and 72 hours post
initial injection displayed slower reaction times to the CS+ stimulus.
(B) In comparison to vehicle treatment, mice treated with 2×-LPS
displayed significantly reduced magazine entries. (C) There was no
difference detected in inactive-hole entries or a change in percentage
free-feeding weight (D). Results are expressed as mean ± SEM.
n = 5/vehicle, n = 10/LPS
0.25 mg/kg, n = 5/LPS 0.50 mg/kg. ANOVA indicates
analysis of variance; CS+, conditioned stimulus; LPS,
lipopolysaccharide; SEM, standard error of the mean.#P < .05 by 2-way ANOVA. *P < .05
and **P < .01 by Tukey multiple comparisons relative
to vehicle treatment.Notably, all treatment groups had comparable body weights during Pavlovian
conditioning, indicating that decreases in body weight at the doses tested is
not a confounding variable affecting acquisition of conditioning in these
experiments (Figure
2D).
Dual-LPS treatment impairs reference memory
To further investigate the effects of 2×-LPS administration on cognitive
function, we assessed memory in mice utilizing the 8-arm radial maze (8-ARM).
Our results show that 0.25 mg/kg LPS does not significantly affect short-term
memory compared to vehicle treatment (F1,11 = 1.44,
P = .25) (Figure 3A). Interestingly, 0.25 mg/kg LPS treatment induces deficits
in reference memory (Figure
3B) compared to vehicle-treated counterparts
(F1,11 = 7.98, P = .01); however, there was no
effect of training across sessions (F4,44 = 1.12,
P = .35) or an interaction (F4,44 = 2.15,
P = .08). As denoted by significantly lower reference
memory ratios in comparison to vehicle-treated mice, mice administered LPS
committed a higher frequency of incorrect entries into arms that never contained
a reward, in relation to entries into arms that previously contained a reward.
This suggests that LPS-induced neuroinflammation can result in prolonged
impairment of reference memory (long-term memory), as these deficits persisted
up to 144 hours post T0 LPS administration.
Figure 3.
Effects of 2× LPS treatment on radial 8-arm maze. (A) Double treatment
with LPS 0.25 mg/kg showed no effect on working memory compared to
vehicle treatment; however, reference memory was impaired (B). ANOVA
indicates analysis of variance; LPS, lipopolysaccharide.
#P < .05 by 2-way ANOVA. *P < .05
and **P < .01 by Tukey multiple comparisons relative
to vehicle treatment.
Effects of 2× LPS treatment on radial 8-arm maze. (A) Double treatment
with LPS 0.25 mg/kg showed no effect on working memory compared to
vehicle treatment; however, reference memory was impaired (B). ANOVA
indicates analysis of variance; LPS, lipopolysaccharide.#P < .05 by 2-way ANOVA. *P < .05
and **P < .01 by Tukey multiple comparisons relative
to vehicle treatment.
Effects of LPS administration on motor skill learning
To interrogate whether 2×-LPS injection treatment had a significant effect on
motor skill learning, we tested each group of mice on the accelerated rotarod.
As depicted in Figure 4,
we did not detect drug treatment effects on rotarod performance
(F2,14 = 1.83, P = .19); however, there was an
effect of rotarod training (F2,28 = 3.96, P = .03)
as all treatment groups improved motor performance over time, suggesting that
2×-LPS treatment does not impair motor coordination or acquisition of motor
skill learning.
Figure 4.
Effects of 2× LPS treatment on motor coordination. Compared to vehicle,
mice treated with dual-LPS showed no deficits in motor skill learning on
the accelerated rotarod. Results are expressed as mean ± SEM
(n = 5/group). LPS indicates lipopolysaccharide;
SEM, standard error of the mean.
Effects of 2× LPS treatment on motor coordination. Compared to vehicle,
mice treated with dual-LPS showed no deficits in motor skill learning on
the accelerated rotarod. Results are expressed as mean ± SEM
(n = 5/group). LPS indicates lipopolysaccharide;
SEM, standard error of the mean.
Effect of LPS treatment on sensorimotor gating startle responses
Sensorimotor gating is the pre-attentive involuntary reduction of motor responses
cued by a sensory event. Prepulse inhibition is the inhibition of reflexive
motor response to a startling auditory pulse prior to presentation of a
subthreshold prepulse. Due to deficits in sensorimotor gating reported in
numerous neurocognitive disorders, we questioned whether mice treated with
double-LPS injections would displayed reductions in PPI. Our results revealed
that sensorimotor gating at 16 hours following T0 of 0.50 mg/kg LPS
is intact compared to vehicle-treated mice (F1,33 = 1.98,
P = .16), as PPI improved upon increased prepulse intensity
(F2,33 = 23.31, P < .0001; Figure 5A). In addition,
LPS treatment 16 hours post T0 injection did not significantly alter
startle response (Figure
5B) compared to vehicle-treated controls
(t11 = 0.88, P = .39). Analysis
of PPI 24 hours post T0 LPS treatment (Figure 5C) revealed that PPI was
unaffected as sensorimotor gating improved upon increased prepulse intensity
(F2,33 = 9.07, P = .0007), and there was no
treatment effect (F1,33 = 3.37, P = .06).
Interestingly, mice treated with 0.50 mg/kg LPS displayed suppressed startle
response compared to vehicle treated controls (t11 = 3.71,
P = .003; Figure 5D).
Figure 5.
Prepulse inhibition (PPI) and startle response in mice treated with 2×
LPS. (A) Sensorimotor gating tested 16 hours after initial injection LPS
did not show significant difference in PPI compared to vehicle treatment
at 4 dB (PP4), 8 dB (PP8), or 16 dB (PP16). (B) Mice tested 16 hours
after initial LPS treatment showed no differences in startle response
compared to vehicle treatment. (C) Mice tested for sensorimotor gating
24 hours after initial LPS treatment did not show any differences in PPI
compared to vehicle; however, LPS treatment did result in decreased
startle response relative to vehicle treatment at 24 hours (D). Results
are expressed as mean ± SEM. HPLC indicates high-performance liquid
chromatography; LPS, lipopolysaccharide; mPFC, medial pre-frontal
cortex; SEM, standard error of the mean.
**P < .01, Student t test
(n = 7/vehicle and n = 6/LPS
0.50 mg/kg).
Prepulse inhibition (PPI) and startle response in mice treated with 2×
LPS. (A) Sensorimotor gating tested 16 hours after initial injection LPS
did not show significant difference in PPI compared to vehicle treatment
at 4 dB (PP4), 8 dB (PP8), or 16 dB (PP16). (B) Mice tested 16 hours
after initial LPS treatment showed no differences in startle response
compared to vehicle treatment. (C) Mice tested for sensorimotor gating
24 hours after initial LPS treatment did not show any differences in PPI
compared to vehicle; however, LPS treatment did result in decreased
startle response relative to vehicle treatment at 24 hours (D). Results
are expressed as mean ± SEM. HPLC indicates high-performance liquid
chromatography; LPS, lipopolysaccharide; mPFC, medial pre-frontal
cortex; SEM, standard error of the mean.**P < .01, Student t test
(n = 7/vehicle and n = 6/LPS
0.50 mg/kg).
Discussion
Neuroinflammatory responses have increasingly garnered investigative interest to
determine its involvement in the pathogenesis of neuropsychiatric disease.[32] Indeed, aberrant tryptophan metabolism resulting from inflammatory sequelae
has been shown to play a potential role in the development of impairments of behavior.[33] Therefore, the objective of this study was to investigate the role of
neuroinflammation induced by consecutive peripheral LPS insults on cognitive
function. Our data show that immune activation by repeated systemic LPS
administration increased kynurenine and KYNA metabolism in the mPFC, in conjunction
with deficits in acquisition of Pavlovian responding. These findings are in
agreement with previous studies showing brain KP modulation following consecutive
LPS administration albeit at a dose established to induce depressive like symptomatology[34] and impaired reward motivated learning.[1,24] Bacterial, viral, and
parasitical infections are associated with activation of Toll-like receptors (TLRs)
signaling, which can be activated experimentally by LPS. The induction of the KP via
TLR activation provides a potential mechanism by which changes in kynurenine
metabolism may affect brain development. For instance, studies have shown that rats
administered perinatal influenza virus induces cerebral KP metabolism, thereby
impairing sensorimotor function into adulthood.[35] In line with this study, a recent publication shows that activation of TLR4
by LPS increase KYNA production in human peripheral monocytes.[36]The assimilation of pooled sensory modalities allows us to adapt to various environments.[37] PPI is the ability of a non-startling pulse to inhibit responding to a
subsequent startling “pulse” or stimulus. Deficits in sensorimotor gating, as
measured by PPI, are well described in patients diagnosed with SCZ and other
psychiatric disorders.[38,39] Inadequacies in sensorimotor gating are suspected to contribute
to sensory overload, cognitive fragmentation, and interceptive stimuli which may
result in psychotic symptoms and cognitive decencies. Interestingly, our current
study supports our previous investigation demonstrating that consecutive LPS
administration had no effects on PPI, although it significantly impairs startle responses.[24] It is worth mentioning that Custódio et al[40] reported decreased PPI performance 24 hours after a single i.p. injection of
0.5 mg/kg LPS, although this study was conducted using the SWR/J inbred strain mice.
Investigations of inbred laboratory rat and mice strains revealed that PPI
performance is a genetic trait and genetic background is an important contributor to
PPI behavior.[41] Thus, the discrepancy between the 2 studies is likely an effect of mouse
strain and experimental methodologies. Given that the effects of LPS on brain
function can be persistent well after the immediate sickness effects, it is possible
that assessment of PPI at a later time point may reveal latent PPI deficits. Indeed,
additional investigations are warranted to further delineate genetic mechanisms that
may underlie sensorimotor gating.Perhaps the most intriguing finding of our study was the reduction in reference
memory capacity that persisted 144 hours after the initial LPS treatment during the
8-arm radial maze task. The important role of working memory for short-term
information guidance and analysis of complex behavior has been well recognized.[42] Of interest, neocortical brain regions such as the mPFC have been shown to be
involved in working memory and reference spatial memory.[43,44] The significant increase in
KYNA within the mPFC shown in our study may support the hypothesis of LPS-induced
neuroinflammation contributing to cognitive impairments, potentially via the
antagonistic action of KYNA on nAChR receptors. In addition, our work provides
evidence supporting the notion that working and reference memory are regulated by
different brain systems as working memory was not altered by dual-LPS treatment.
Considering the dynamic interactions between the mPFC and the hippocampus, further
studies are necessary to interrogate the effects of double-LPS treatment on
cognition.Admittedly, there are some limitations to our study. Lipopolysaccharide activates a
number of pathways including TLR-4 and elicits several pro-inflammatory responses.
As such, LPS is not exclusive and activates many pathways involved in inflammation
and is not specific toward the induction of the KP pathway. It is a limitation of
our study that specific brain-penetrable KATII inhibitors were not used to decrease
elevated KYNA levels resulting from 2×-LPS treatment. In addition, the use of an
Alzet implantable osmotic pump could have been utilized to infuse
l-kynurenine, thus increasing KYNA levels without the need for LPS which
would have allowed us to better dissociate the effects of elevated KYNA on cognitive
function apart from the inflammatory effects. Moving forward, a long-term study
should be performed to determine if impairments in cognitive function resulting from
2×-LPS return to normal after longer periods of time. Clinically, sex difference in
cognitive function have been reported in schizophrenicpatients with studies
indicating male schizophrenicpatients are afflicted with more serious cognitive
deficits compared to females.[45] For this reason, we have decided to conduct our experiments using only male
mice. However, future study should compare the possible difference between
sexes.In summary, intraperitoneal administration of dual-LPS injections strongly induce the
KP metabolism resulting in increased production of KYNA. Furthermore, our findings
provide support for the feasibility of LPS-induced neuroinflammatory process
contributing to cognitive impediment.
Authors: Klas R Linderholm; Elisabeth Skogh; Sara K Olsson; Marja-Liisa Dahl; Maria Holtze; Göran Engberg; Martin Samuelsson; Sophie Erhardt Journal: Schizophr Bull Date: 2010-08-20 Impact factor: 9.306
Authors: A Parwani; E J Duncan; E Bartlett; S H Madonick; T R Efferen; R Rajan; M Sanfilipo; P B Chappell; S Chakravorty; S Gonzenbach; G N Ko; J P Rotrosen Journal: Biol Psychiatry Date: 2000-04-01 Impact factor: 13.382
Authors: Ikwunga Wonodi; Robert P McMahon; Nithin Krishna; Braxton D Mitchell; Judy Liu; Matthew Glassman; L Elliot Hong; James M Gold Journal: Schizophr Res Date: 2014-11-14 Impact factor: 4.939
Authors: C M Sellgren; M E Kegel; S E Bergen; C J Ekman; S Olsson; M Larsson; M P Vawter; L Backlund; P F Sullivan; P Sklar; J W Smoller; P K E Magnusson; C M Hultman; L Walther-Jallow; C I Svensson; P Lichtenstein; M Schalling; G Engberg; S Erhardt; M Landén Journal: Mol Psychiatry Date: 2015-12-15 Impact factor: 15.992